Endurant Capital Management LP Gilead Sciences, Inc. Transaction History

Endurant Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$61.87 - $69.38 $9.64 Million - $10.8 Million	-155,793 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$62.53 - $70.05 $9.74 Million - $10.9 Million	155,793 New	155,793 $10.1 Million
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $624,470 - $814,885	-10,315 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $5.17 Million - $5.73 Million	-72,548 Reduced 87.55%	10,315 $796,000
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $2.31 Million - $2.7 Million	35,663 Added 75.56%	82,863 $5.87 Million
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $3.44 Million - $4.19 Million	47,200 New	47,200 $3.56 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $1.95 Million - $2.28 Million	-27,357 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $1.97 Million - $2.34 Million	27,357	27,357 $2.22 Million

1,879

1.02B

12M

8.96M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $105B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.